Dr Reddy's Labs gets USFDA nod for lice treatment lotion XEGLYZE in US
XEGLYZE is indicated for the topical treatment of head lice infestation in patients 6 months of age and older.
Hyderabad and Princeton: Drugmaker, Dr Reddy's Laboratiories recently announced that the company has received approval from the U.S. Food and Drug Administration (USFDA) for its lice treatment lotion- XEGLYZE (abametapir) lotion, 0.74%, a 505(b)(1) NDA.The approval triggers the contractual pre-commercialization milestone of $20 million payable to Hatchtech Pty Ltd. XEGLYZE is indicated...
Hyderabad and Princeton: Drugmaker, Dr Reddy's Laboratiories recently announced that the company has received approval from the U.S. Food and Drug Administration (USFDA) for its lice treatment lotion- XEGLYZE (abametapir) lotion, 0.74%, a 505(b)(1) NDA.
The approval triggers the contractual pre-commercialization milestone of $20 million payable to Hatchtech Pty Ltd.
XEGLYZE is indicated for the topical treatment of head lice infestation in patients 6 months of age and older.
The company is working to commercialize this product through partners.
INDICATION AND USAGE
For 2 weeks after XEGLYZE application, avoid taking drugs that are substrates of CYP3A4, CYP2B6 or CYP1A2. Otherwise, avoid use of XEGLYZE.
Most common adverse reactions (incidence of ≥ 1%) were erythema, rash, skin burning sensation, contact dermatitis, vomiting, eye irritation, pruritus, and hair color changes.
These are not all the side effects associated with XEGLYZE.
Read also: FY21: Dr Reddy's Q1 results to be released on July 29th
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd